We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Ion Platform's 52% Growth Make It ISRG's Next Growth Engine?
Read MoreHide Full Article
Key Takeaways
ISRG's Ion platform recorded significant growth in the third quarter with 52% procedure growth.
Study data demonstrated 84.6% diagnostic yield for ISRG's Ion compared to conventional bronchoscopy.
Adoption of ISRG's Ion platform boosted lung cancer detection, implying higher procedure growth potential.
Intuitive Surgical’s (ISRG - Free Report) third-quarter performance highlights a pivotal shift in its platform mix, with robotic bronchoscopy, formerly a peripheral initiative, rapidly emerging as a core growth engine. Ion platform procedures surged 52% year over year to just under 38,000, far outpacing the still-strong 19% growth of da Vinci procedures. While da Vinci remains the financial backbone, Ion’s accelerating adoption and expanding clinical validation signal a maturing segment with the potential to reshape ISRG’s future revenue stack.
Intuitive Surgical is expanding the platform’s clinical advantage, driven by AI-enabled planning, real-time navigation and multimodal imaging. ISRG reported FDA clearance of new Ion software featuring real-time AI airway navigation and tomosynthesis to improve precision, especially in facilities without cone-beam CT.
More importantly, new data from the Zurich randomized controlled trial may significantly boost Ion’s potential, as it demonstrated a diagnostic yield of 84.6% for Ion plus mobile cone-beam CT versus 23.1% for conventional bronchoscopy, despite nodules averaging only 11 mm. The study also showed a nearly 30-percentage-point jump in Stage 1A lung cancer detection after Ion adoption — exactly the type of upstream clinical impact that can structurally increase procedure volumes.
Lung cancer remains the world’s deadliest cancer, and earlier-stage detection is the single biggest driver of survival and cost-efficiency. Ion is positioned directly in this clinical gap. Although da Vinci’s installed base of nearly 10,800 systems remains far larger than Ion’s roughly 950 systems, Ion’s 14% utilization growth and its expanding AI-enabled capabilities suggest increasing throughput and more durable economics for pulmonary programs.
At present, Ion generates a much smaller portion of revenues than da Vinci’s leading instruments-and-accessories segment. But if the Zurich trial data catalyzes stronger adoption across global lung screening programs, Ion could transition from a high-growth adjunct to ISRG’s next scaled franchise — one capable of materially reshaping the company’s long-term growth runway.
Peer Updates
Johnson & Johnson’s (JNJ - Free Report) robotic-bronchoscopy platform, the MONARCH Platform, continues to advance significantly. J&J recently announced data from the TARGET study, which demonstrated that clinicians reached small, peripherally located lung nodules in 98.7% of cases and achieved an 83.2% diagnostic yield using the MONARCH system.
In March 2025, the company received FDA 510(k) clearance for the next-gen MONARCH QUEST upgrade, featuring AI-powered navigation (via NVIDIA RTX architecture) and integration with GE HealthCare OEC 3D mobile CBCT to enhance real-time targeting and precision. J&J has also secured regulatory clearance in China, making MONARCH the first minimally invasive robot-assisted lung procedure platform approved in that market. With these developments, J&J is positioning MONARCH as a frontrunner in enabling earlier lung lesion diagnosis and extending its procedural reach deeper into the lung periphery.
Medtronic plc’s (MDT - Free Report) bronchoscopy strategy centers on its ILLUMISITE Platform, a fluoroscopic navigation system (not yet a full robotic bronchoscopy system) that employs digital tomosynthesis and real-time CT-to-body divergence correction. Clinical data for ILLUMISITE show a 79.3% diagnostic accuracy at 12-month follow-up versus 73.6% for CT-guided biopsy, and substantially fewer complications (5.8% vs. 31%).
The platform also demonstrated near parity in diagnostic yield compared with the competitive Ion robotic system in the RELIANT trial (75.5% vs. 77.8%). While Medtronic has not yet publicly launched a dedicated robotic bronchoscopy system, it is actively investing in its broader robotics and AI hub and developing next-wave solutions across surgery.
Thus, for Medtronic, ILLUMISITE serves as a strong stepping stone in bronchoscopic navigation with robotic ambitions in view.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have gained 4.8% in the year-to-date period compared with 0.2% growth for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 57.91, above the industry average. But, it is still lower than its five-year median of 71.53. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies a 17.3% rise from the year-ago period’s level.
Image: Shutterstock
Will Ion Platform's 52% Growth Make It ISRG's Next Growth Engine?
Key Takeaways
Intuitive Surgical’s (ISRG - Free Report) third-quarter performance highlights a pivotal shift in its platform mix, with robotic bronchoscopy, formerly a peripheral initiative, rapidly emerging as a core growth engine. Ion platform procedures surged 52% year over year to just under 38,000, far outpacing the still-strong 19% growth of da Vinci procedures. While da Vinci remains the financial backbone, Ion’s accelerating adoption and expanding clinical validation signal a maturing segment with the potential to reshape ISRG’s future revenue stack.
Intuitive Surgical is expanding the platform’s clinical advantage, driven by AI-enabled planning, real-time navigation and multimodal imaging. ISRG reported FDA clearance of new Ion software featuring real-time AI airway navigation and tomosynthesis to improve precision, especially in facilities without cone-beam CT.
More importantly, new data from the Zurich randomized controlled trial may significantly boost Ion’s potential, as it demonstrated a diagnostic yield of 84.6% for Ion plus mobile cone-beam CT versus 23.1% for conventional bronchoscopy, despite nodules averaging only 11 mm. The study also showed a nearly 30-percentage-point jump in Stage 1A lung cancer detection after Ion adoption — exactly the type of upstream clinical impact that can structurally increase procedure volumes.
Lung cancer remains the world’s deadliest cancer, and earlier-stage detection is the single biggest driver of survival and cost-efficiency. Ion is positioned directly in this clinical gap. Although da Vinci’s installed base of nearly 10,800 systems remains far larger than Ion’s roughly 950 systems, Ion’s 14% utilization growth and its expanding AI-enabled capabilities suggest increasing throughput and more durable economics for pulmonary programs.
At present, Ion generates a much smaller portion of revenues than da Vinci’s leading instruments-and-accessories segment. But if the Zurich trial data catalyzes stronger adoption across global lung screening programs, Ion could transition from a high-growth adjunct to ISRG’s next scaled franchise — one capable of materially reshaping the company’s long-term growth runway.
Peer Updates
Johnson & Johnson’s (JNJ - Free Report) robotic-bronchoscopy platform, the MONARCH Platform, continues to advance significantly. J&J recently announced data from the TARGET study, which demonstrated that clinicians reached small, peripherally located lung nodules in 98.7% of cases and achieved an 83.2% diagnostic yield using the MONARCH system.
In March 2025, the company received FDA 510(k) clearance for the next-gen MONARCH QUEST upgrade, featuring AI-powered navigation (via NVIDIA RTX architecture) and integration with GE HealthCare OEC 3D mobile CBCT to enhance real-time targeting and precision. J&J has also secured regulatory clearance in China, making MONARCH the first minimally invasive robot-assisted lung procedure platform approved in that market. With these developments, J&J is positioning MONARCH as a frontrunner in enabling earlier lung lesion diagnosis and extending its procedural reach deeper into the lung periphery.
Medtronic plc’s (MDT - Free Report) bronchoscopy strategy centers on its ILLUMISITE Platform, a fluoroscopic navigation system (not yet a full robotic bronchoscopy system) that employs digital tomosynthesis and real-time CT-to-body divergence correction. Clinical data for ILLUMISITE show a 79.3% diagnostic accuracy at 12-month follow-up versus 73.6% for CT-guided biopsy, and substantially fewer complications (5.8% vs. 31%).
The platform also demonstrated near parity in diagnostic yield compared with the competitive Ion robotic system in the RELIANT trial (75.5% vs. 77.8%). While Medtronic has not yet publicly launched a dedicated robotic bronchoscopy system, it is actively investing in its broader robotics and AI hub and developing next-wave solutions across surgery.
Thus, for Medtronic, ILLUMISITE serves as a strong stepping stone in bronchoscopic navigation with robotic ambitions in view.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have gained 4.8% in the year-to-date period compared with 0.2% growth for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 57.91, above the industry average. But, it is still lower than its five-year median of 71.53. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies a 17.3% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.